|
|
Background: This study aimed to investigate the expression level of methyltransferase-like protein 7A (METTL7A) in primary acute myeloid leukemia (AML) and to evaluate its clinical significance.
Methods: Bone marrow samples from 60 newly diagnosed AML patients were collected as the experimental group, while 20 normal bone marrow samples served as the control group. Clinical data of the AML patients were also collected. The METTL7A expression levels in the experimental and control groups were measured using real-time PCR (qRT-PCR). The relationship between METTL7A expression and clinicopathological features and prognosis in AML patients was analyzed. The impact of METTL7A expression on overall survival (OS) was evaluated using Kaplan-Meier curves, and prognostic factors affecting AML patients were assessed through Cox regression analysis.
Results: The expression of METTL7A was significantly higher in AML patients compared to controls (p < 0.05). Patients with high METTL7A expression exhibited significantly shorter OS compared to those with low expression (p < 0.05). High METTL7A expression was identified as an independent risk factor for poor prognosis in AML.
Conclusions: METTL7A expression is significantly elevated in AML patients, and its upregulation is associated with adverse clinicopathological features and poor prognosis. These findings suggest that METTL7A may serve as a potential biomarker for diagnosis, disease monitoring, and targeted therapy in AML.
DOI: 10.7754/Clin.Lab.2025.250234
|
